Page last updated: 2024-12-06

deuterium oxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Deuterium Oxide: The isotopic compound of hydrogen of mass 2 (deuterium) with oxygen. (From Grant & Hackh's Chemical Dictionary, 5th ed) It is used to study mechanisms and rates of chemical or nuclear reactions, as well as biological processes. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID24602
CHEMBL ID1232306
CHEBI ID41981
MeSH IDM0026721

Synonyms (71)

Synonym
2h
water-d sub(2)
CHEMBL1232306
d2o ,
deuterium oxide
7789-20-0
deuterium oxide (usan)
D03703
deuterated water
deuterium oxide, 99 atom % d
deuterium oxide, 99.9 atom % d, contains 0.05 wt. % 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid, sodium salt
deuterium oxide, 99.9 atom % d, glass distilled
deuterium oxide, 99.8 atom % d
deuterium oxide, extra, 99.994 atom % d
CHEBI:41981 ,
deuterium oxide, 99.9 atom % d, contains 1 % (w/w) 3-(trimethylsilyl)-1-propanesulfonic acid, sodium salt (dss)
deuterium oxide, standard, 99.98 atom %+/-0.01 atom % d
deuterium oxide, 100%, 99.990 atom % d
deuterium oxide, 99.9 atom % d
deuterium oxide, 99.9 atom % d, ~150 dpm/ml tritium
deuterium oxide, 99.9 atom % d, contains 0.75 wt. % 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid, sodium salt
deuterium oxide, 100%, 99.96 atom % d
deuterium oxide, 100%, >=99.96 atom % d
water-d2
einecs 232-148-9
dideuterium oxide
deuterium oxide [usan]
heavy water
ai3-52352
heavy water-d2
water, heavy (d2-o)
heavy water (d2o)
water(sup 2)-h2
deuterium oxide, 99.9 atom %d
j65bv539m3 ,
hsdb 8190
unii-j65bv539m3
(sup 2)h
W0004
W0002
AKOS015904640
deuterium oxide [mi]
water h-2
XLYOFNOQVPJJNP-ZSJDYOACSA-N
DTXSID4051243 ,
deuterium oxide (water-d2, heavy water)
J-520218
deuterium oxide, filtered, 99.8 atom % d
mfcd00044636
deuterium oxide, 70 atom % d
deuterium oxide, 60 atom % d
deuterium oxide, 100.0 atom % d, >=99.96 atom % d
deuterium oxide, 99.994 atom % d, contains 1 mm terephthalic acid disodium salt, 0.01 % (w/v) dss-d6
deuterium oxide, 99.99 atom % d (for d2o), contains 1% dss-d6
deuterium oxide, vetec(tm) reagent grade, 99.8 atom % d
deuteriumoxide
(~2~h_2_)water
Q155890
deuterium oxide 99.8atom%d
H11944
A934838
deuterium oxide, contains 0.05 wt% d4-tmsp acid, sodium salt
142473-50-5
[(?h)oxy](?h)
water-d2 99.8atom%d, heavy water
deuteriumoxid
(od2)
oxide, deuterium
schweres wasser
((2)h2)water
dtxcid3029865

Research Excerpts

Overview

Deuterium oxide is a molecule that has been used for decades in several studies related to human health.

ExcerptReferenceRelevance
"Deuterium oxide is a molecule that has been used for decades in several studies related to human health. "( Biotechnological Patents Applications of the Deuterium Oxide in Human Health.
Bila, WC; da S Mariano, RM; Galdino, AS; Lamounier, JA; Trindade, MJF, 2017
)
2.16

Effects

Deuterium oxide (D2O) has been shown in previous studies to increase both the fluorescence lifetime and fluorescence intensity of propidium iodide (PI) and ethidium bromide (EB) When bound to nucleic acid structures.

ExcerptReferenceRelevance
"Deuterium oxide (D₂O) has been reported to be active toward various in vitro cell lines in combination with phytochemicals. "( Aquaporin 11-Dependent Inhibition of Proliferation by Deuterium Oxide in Activated Hepatic Stellate Cells.
Cho, N; Kim, HP; Lee, PJ; Park, HJ, 2018
)
2.17
"Deuterium oxide (D2O) has been used to demonstrate that fluid ingested during exercise appears in sweat within 10 minutes."( Appearance of D2O in sweat after oral and oral-intravenous rehydration in men.
Armstrong, LE; Beasley, KN; Casa, DJ; Emmanuel, H; Lee, EC; Maresh, CM; McDermott, BP; Yamamoto, LM, 2011
)
1.09
"Deuterium oxide (D2O) has been shown in previous studies to increase both the fluorescence lifetime and fluorescence intensity of propidium iodide (PI) and ethidium bromide (EB) when bound to nucleic acid structures. "( Interactions of intercalating fluorochromes with DNA analyzed by conventional and fluorescence lifetime flow cytometry utilizing deuterium oxide.
Crissman, HA; Nastasi, AJ; Sailer, BL; Steinkamp, JA; Valdez, JG, 1996
)
1.94
"Deuterium oxide (2H2O) has been added to drinks as a tracer for water to estimate the availability to the body water pool of ingested fluids, but doubts have been raised as to the reliability of the method. "( The use of a deuterium tracer technique to follow the fate of fluids ingested by human subjects: effects of drink volume and tracer concentration and content.
Ball, D; Lambert, CP; Leiper, JB; Maughan, RJ, 1999
)
1.75

Treatment

ExcerptReferenceRelevance
"Pretreatment with deuterium oxide (D2O) has been shown to protect mice against lethal effects of X-rays. "( Radioprotection of cultured cells by preincubation in medium containing deuterium oxide.
Laeng, RH; Laissue, JA; Mini, RL; Schindler, R, 1991
)
0.85

Toxicity

ExcerptReferenceRelevance
"The clinically used mixture of BBG/D2O seems to be safe for clinical use."( Evaluating retinal toxicity of a new heavy intraocular dye, using a model of perfused and isolated retinal cultures of bovine and human origin.
Bartz-Schmidt, KU; Doycheva, D; Januschowski, K; Mueller, S; Schramm, C; Spitzer, MS; Szurman, P, 2012
)
0.38

Pharmacokinetics

ExcerptReferenceRelevance
"Modeling of pharmacokinetic parameters and pharmacodynamic actions requires knowledge of the arterial blood concentration."( Physiologically based pharmacokinetic modeling of arterial - antecubital vein concentration difference.
Levitt, DG, 2004
)
0.32
"A physiologically based pharmacokinetic (PBPK) model for the tissues drained by the antecubital vein (referred to as "arm") is developed."( Physiologically based pharmacokinetic modeling of arterial - antecubital vein concentration difference.
Levitt, DG, 2004
)
0.32
"The kinetic parameters of absorption and distribution of ingested water (300 ml labeled with D(2)O; osmolality <20 mOsm kg(-1)) in the body water pool (BWP) and of its disappearance from this pool were estimated in 36 subjects from changes in plasma or urine deuterium to protium ratio (D/H) over 10 days using one- and two-compartment and a non-compartmental pharmacokinetic models (1-CM, 2-CM and N-CM which applied well to 58, 42 and 100% of the subjects, respectively)."( Pharmacokinetic analysis of absorption, distribution and disappearance of ingested water labeled with D₂O in humans.
du Souich, P; Jimenez, L; Le Bellego, L; Mignault, D; Péronnet, F; Rabasa-Lhoret, R; Vergne, S, 2012
)
0.38

Compound-Compound Interactions

ExcerptReferenceRelevance
"The mechanism of cell damage by ultrasound in combination with hematoporphyrin was studied."( Mechanism of cell damage by ultrasound in combination with hematoporphyrin.
Nishigaki, R; Umemura, K; Umemura, S; Yumita, N, 1990
)
0.28
" Here, we report a method to obtain sub-millisecond temporal resolution and molecular structural information of protein (mis-)folding events by using a microfluidic continuous-flow mixer (MCFM) in combination with Fourier transform infrared (FT-IR) imaging."( Polymeric microfluidic continuous flow mixer combined with hyperspectral FT-IR imaging for studying rapid biomolecular events.
Bhargava, R; Jang, H; Kenis, PJA; Pawate, AS, 2019
)
0.51

Bioavailability

ExcerptReferenceRelevance
" The K+ absorption rate of the seedlings decreased from a value of 39 to 18 mumol g-1 h-1 when the D2O concentration was changed through a range from 0% to 97%."( Water and potassium ion absorption by deuterium oxide resistant winter rye seedlings.
Shibabe, S; Yoda, K, 1985
)
0.54
" Our results suggest that aqueous phosphate is an efficient desorbing anion of p-AsA(ads), which has implications on its bioavailability and mobility in geochemical environments."( ATR-FTIR studies on the nature of surface complexes and desorption efficiency of p-arsanilic acid on iron (oxyhydr)oxides.
Al-Abadleh, HA; Chabot, M; Hoang, T, 2009
)
0.35
"To understand the effect of any biomolecules in specific metabolic pathways in humans, bioavailability and for other basic understanding, stable isotopically-labelled biomolecules (preferably deuterated) is the fundamental pre-requisite."( Tagging of biomolecules with deuterated water (D2O) in commercially important microalgae.
Hayes, J; Moane, S; Murray, P; Saha, SK, 2013
)
0.39
"Increasing the bioavailability of immobilized phosphorus (P) in soil by phosphate-solubilizing bacteria (PSB) is an effective strategy for sustainable agronomic use of P and for mitigating the P crisis."( D
Bi, QF; Cui, L; Li, HZ; Pu, Q; Yang, K; Zheng, BX, 2019
)
0.51

Dosage Studied

10 women and 10 men were dosed with deuterium oxide (0.1%) to estimate total body water (TBW) A subset of 24 pups was dosed twice to estimate changes in body composition and water flux. Spillage of deuterIUM oxide solution during dosing was a major challenge in the Kenya context.

ExcerptRelevanceReference
" However, the chronic D2O treatment appeared to have little effect on the phenylephrine and potassium chloride induced dose-response curves of SHR and WKY rats, producing a decreased maximal contraction of the potassium chloride dose-response curve of SHR only."( The effect of chronic and acute administration of deuterium oxide (D2O) on vascular smooth muscle contraction in spontaneously hypertensive and Wistar-Kyoto rats.
Liepins, A; McWilliam, TM; Rankin, AJ, 1992
)
0.54
" The dose-response was linear in all genotypes tested."( A circadian clock of Drosophila: effects of deuterium oxide and mutations at the period locus.
Dowse, H; Ringo, J; White, L, 1992
)
0.54
" Blood samples (20 ml) were obtained before dosing and every 4 h thereafter."( Measurement of triglyceride synthesis in humans using deuterium oxide and isotope ratio mass spectrometry.
Jones, PJ; Leitch, CA, 1991
)
0.53
" Sixty percent D2O also depressed a calcium contraction dose-response curve by approximately 25%."( Deuterium oxide reduces agonist and depolarization-induced contraction of rat aortic rings.
Liepins, A; McWilliam, TM; Rankin, AJ, 1990
)
1.72
" The S-shaped dose-response relationship with D2O was shifted to the left in the patients with BR to exercise compared to patients without (P less than 0 X 025)."( Release of histamine from leucocytes and its determinants in vitro in relation to bronchial responsiveness to inhaled histamine and exercise in vivo.
Degenhart, HJ; Kerrebijn, KF; Neijens, HJ; Raatgeep, HC, 1982
)
0.26
" The findings strongly suggest a non-cytotoxic secretory process requiring the presence of two quaternary ammonium groups as suggested by the rarity of release with tubocurarine; inhibition of succinyldicholine (suxamethonium)-induced histamine release by serum cholinesterase treatment, acetylcholine and tubocurarine; and the bell-shaped dose-response curve, particularly with suxamethonium."( Characteristics of basophil histamine release by neuromuscular blocking drugs in patients with anaphylactoid reactions.
Assem, ES, 1984
)
0.27
" D2O stimulated the hexose monophosphate shunt (HMS) activity of resting neutrophils in a dose-response fashion."( Effect of deuterium oxide on neutrophil oxidative metabolism, phagocytosis, and lysosomal enzyme release.
Tsan, MF; Turkall, RM, 1982
)
0.67
"To develop equations for predicting body composition, mature Holstein cows (n = 21) were slaughtered at three physiological stages (-7, 63, and 269 d postpartum) after consecutive intravenous dosing with urea and D2O."( Prediction of body composition of dairy cows at three physiological stages from deuterium oxide and urea dilution.
Andrew, SM; Erdman, RA; Waldo, DR, 1995
)
0.52
" Blood samples were obtained prior to dosing and every 4 h thereafter."( Measurement of human lipogenesis using deuterium incorporation.
Jones, PJ; Leitch, CA, 1993
)
0.29
" A large body of clinical data shows the safety of deuterium at the dosage that would be given with this vaccine."( Development of a more thermostable poliovirus vaccine.
Lemon, SM; Milstien, JB; Wright, PF, 1997
)
0.3
" Thirty-three pups were dosed with deuterium oxide to estimate total body water (TBW) and a subset of 24 was dosed twice to estimate changes in body composition and water flux."( Weaning mass affects changes in body composition and food intake in harbour seal pups during the first month of independence.
Bowen, WD; Iverson, SJ; Muelbert, MM,
)
0.41
" The results show that both CL intensity and cell mortality of lymphocytes increase with the increase of the radiation dose when the dosage is no more than 3 Gy, suggesting a positive relationship between the degree of lymphocyte cell damage and the amount of ROS generated."( Evaluation of the degree of medical radiation damage with a highly sensitive chemiluminescence method.
Gao, B; Li, X; Wei, Y; Xing, D; Zhu, D,
)
0.13
"Following collection of a fasting baseline urine sample, 10 women and 10 men were dosed with deuterium oxide (0."( Implications of the variability in time to isotopic equilibrium in the deuterium dilution technique.
Byrne, NM; Colley, RC; Hills, AP, 2007
)
0.56
" Similar rates of cholesterol synthesis were estimated when comparing data in the group over the different weeks, but better reproducibility was observed when comparing replicate determinations of cholesterol synthesis in the same nonhuman primate during the respective dosing periods."( Quantifying cholesterol synthesis in vivo using (2)H(2)O: enabling back-to-back studies in the same subject.
Andrews-Kelly, G; Azer, K; Bhat, G; Dunn, K; Herath, K; Hubbard, BK; Johns, DG; Johnson, C; Kulick, A; Mahsut, A; Miller, PL; Previs, SF; Roddy, TP; Wang, SP; Xu, J, 2011
)
0.37
" Spillage of deuterium oxide solution during dosing was a major challenge in the Kenya context."( WinFood data from Kenya and Cambodia: constraints on field procedures.
Estambale, B; Friis, H; Kinyuru, J; Konyole, S; Nanna, R; Omollo, S; Owino, VO; Owuor, B; Skau, J, 2015
)
0.79
" Recent advances in the technique have included attempts to make the method less invasive by using innovative methods for dosing and sample collection."( Using doubly-labelled water to measure free-living energy expenditure: Some old things to remember and some new things to consider.
Hambly, C; Speakman, JR, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
NMR solventA solvent used in nuclear magnetic resonance (NMR) spectroscopy.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
waterAn oxygen hydride consisting of an oxygen atom that is covalently bonded to two hydrogen atoms
deuterated compoundAny isotopically modified compound that has one or more hydrogen atoms replaced by deuterium.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (2,295)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990395 (17.21)18.7374
1990's501 (21.83)18.2507
2000's718 (31.29)29.6817
2010's578 (25.19)24.3611
2020's103 (4.49)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 95.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index95.43 (24.57)
Research Supply Index7.79 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index175.65 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (95.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials52 (2.20%)5.53%
Reviews52 (2.20%)6.00%
Case Studies2 (0.08%)4.05%
Observational3 (0.13%)0.25%
Other2,252 (95.38%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (10)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
BioImpedentiometry and Lung UltraSound Examination to MOnitor cONgestion in Heart Failure [NCT02394470]60 participants (Actual)Interventional2016-01-31Completed
Tanita® BIA System Validation [NCT02118675]150 participants (Actual)Observational2014-01-31Completed
"Concurrent Assessment of Skeletal Muscle Mass and Synthesis/Breakdown in Old Age: Defining Diagnostics and the Aetiology of Sarcopenia to Identify At-risk Individuals and Appropriate Countermeasures" [NCT04114383]37 participants (Actual)Observational2016-06-07Completed
Metabolism of Lipids in Advanced Cancer [NCT00962234]12 participants (Actual)Observational2009-10-31Terminated(stopped due to ethics approval not renewed by Study Group)
Cold Induced Changes in Human Subcutaneous White Adipose [NCT02596776]Early Phase 126 participants (Actual)Interventional2016-03-31Completed
Deciphering the Enigma of Postprandial Hyperinsulinaemic Hypoglycaemia After Bariatric Surgery, Part 1 A: Assessing Insulin Turnover Using an In-vivo Deuterated Water Experiment. A Proof-of-concept Study. [NCT04332289]4 participants (Actual)Observational2020-07-09Completed
The Sensitivity of Differing D2O Dosing Strategies and Mass Spectrometry-based Analytical Techniques to Determine Rates of Muscle Protein Synthesis in Young Men and Women [NCT04256343]0 participants (Actual)Interventional2020-05-01Withdrawn(stopped due to COVID and lack of funding)
A Pilot Study to Determine the Effects of the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) [NCT01752426]Phase 1/Phase 230 participants (Actual)Interventional2012-12-17Completed
Feasibility Study: Determination of the Effect of Ultherapy® Treatment on the Rate of Collagen Synthesis in Normal Skin [NCT01708525]2 participants (Actual)Interventional2012-08-31Completed
Discovery of Biological Signatures for Cruciferous Vegetable Intake: Integration of the Broccoli- and Host-derived Metabolome and the Microbiome [NCT04641026]83 participants (Actual)Interventional2021-02-22Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01708525 (1) [back to overview]Rate of Collagen Synthesis
NCT01752426 (2) [back to overview]Change in Leukemia Cell Death
NCT01752426 (2) [back to overview]Percentage of Recently Born Leukemia Cells Mobilized Into the Blood by PCI-32765 Treatment

Rate of Collagen Synthesis

Resected tissue will be analyzed to determine the rate of collagen synthesis in tissue treated with Ultherapy® compared to non-treated tissue. (NCT01708525)
Timeframe: 4 weeks post-treatment

,
Interventionpercentage of new collagen synthesized (Number)
Subject 1, Type I CollagenSubject 1, Type III CollagenSubject 2, Type I CollagenSubject 2, Type III Collagen
Ultherapy®-Treated Tissue21.2251.8029.6968.13
Untreated Tissue15.7136.1118.5350.34

[back to top]

Change in Leukemia Cell Death

Stable isotopic labeling with deuterated water (2^H2O) to measure directly the effects of PCI-32765 (ibrutinib) on leukemia cell death in the peripheral blood of participants . (NCT01752426)
Timeframe: every three months, up to one year

Interventionpercentage of cell death (Median)
Daily death rate of blood cells before therapyDaily death rate of blood cells after therapy
Heavy Water + PCI-327650.181.5

[back to top]

Percentage of Recently Born Leukemia Cells Mobilized Into the Blood by PCI-32765 Treatment

Measurement of the fraction of recently born versus older leukemia cells in the peripheral blood of participants before and during PCI-32765 therapy, to determine the effects of PCI-32765 (ibrutinib) therapy on the birth rates of the leukemia cells. (NCT01752426)
Timeframe: every three months, up to one year

Interventionpercentage of leukemia cells (Median)
Daily cell birth rate before therapyDaily cell birth rate during therapy
Heavy Water + PCI-327650.390.05

[back to top]